Neurofeedback in Clinical High Risk
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-30
SponsorBoston VA Research Institute, Inc.
About this trial
The goal of this trial is to test whether fMRI based neurofeedback from default mode network (DMN) will reduce DMN hyperconnectivity in clinical high risk individuals, which will lead to reductions in clinical symptoms and improve cognitive performance.
Eligibility criteria
Qualifiers
12-30 years old
Native speaker or early learner (by age of 6) of English
COPS diagnostic criteria met For HC Inclusion
12-30 years old
Disqualifiers
Meeting DSM-5 criteria for lifetime psychotic disorder, including affective psychoses
WASI-II IQ < 70
Psychosis risk symptoms caused by other psychiatric disorders (including substance use/misuse)
Congenital or acquired CNS disorder that could account for psychosis-risk or cognitive symptoms
Trial design
Treatments tested in this trial
- fMRI based neurofeedback
Treatment groups
40 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov